<HTML>

<HEAD>
<TITLE>Клинические аспекты тромболитической терапии при остром инфаркте миокарда</TITLE>
<META NAME="keywords" CONTENT="атеросклероз, тромболизис, ишемия, инфаркт, кардиология">

<link rel=stylesheet href="athero.css" type="text/css">

</head>
<BODY BGCOLOR="#ffffff" link=#993366 vlink=#993366 alink=#993366 topmargin=0 leftmargin=0>

<table cellspacing=0 cellpadding=0 border=0 width=740>
<tr><td width=230 valign=top><iframe width=220 height=1800 frameborder=0 vspace=0 hspace=0 marginwidth=0 marginheight=0 scrolling=no src="nav_root.htm"></iframe>

</td><td valign=top><img src="http://counter.rambler.ru/top100.cnt?352447" alt="" width=1 height=1 border=0 align=right>

<h2><a href=guidelines.htm>Образовательные статьи</a></h2>

<h3>Клинические аспекты тромболитической терапии при остром инфаркте миокарда</h3>

<p><a href=tlt_txt.htm>Вернуться к статье</a>

<p><b>Литература</b></p>
<ol>

<li>The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction syndromes in patients presenting with St-segment elevation. Eur Heart J 2003; 24: 28-66.
<li>ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction. 1999 Uptate. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Web version.
<li>H. White, F. Van de Werf. Thrombolysis for Acute Myocardial Infarction. Circulation 1998; 97: 1632-1646.
<li>Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311–22.
<li>E. Boersma et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771-775.
<li>ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349–60.
7.       <li>ACC/AHA guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002; <a href=http://www.acc.org/clinical/guidelines/unstable> http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.</a> 
<li>ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction—2002: Summary Article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).<a href=http://www.circulationaha.org> http://www.circulationaha.org</a>.
<li>The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology.  Management of acute coronary syndromes in patients presenting without persisting St-segment elevation. Eur Heart J 2002; 23: 1809-1840.
<li>Лечение острого коронарного синдрома без стойких подъемов сегмента ST на ЭКГ. Российские рекомендации (ВНОК). Приложение к журналу “Кардиология” 2001, №10. 
<li>A. Langer et al., for the LATE Study Investigators. Late Assessment of Thrombolytic Efficacy (LATE) Study: prognosis in patients with non-Q wave myocardial infarction. JACC 1996; 27: 1327–1332.
<li>H. White. Thrombolytic therapy in the elderly. Lancet 2000; 356: 2028–2030.
<li>J. Estess, E. Topol. Fibrinolytic treatment for elderly patients with acute
myocardial infarction. Heart 2002; 87: 308–311.
<li>V. Menon, J. Hochman. Management of cardiogenic shock complicating acute myocardial infarction. Heart 2002; 88: 531–537.
<li>A. Maggioni et al. The Gruppo Italiano per lo Studio della Sopravvivenza nell Infarcto Miocardico II (GISSI-2) and the International Study Group. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med 1992; 327: 1–6.
<li>H. White et al., for the GUSTO-I Investigators. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I Trial. Circulation 1996; 94: 1826–1833.
<li>C. Weston,  P. Avery. Thrombolysis following pre-hospital cardiopulmonary resuscitation. Int J Cardiol 1992; 37: 195–198.
<li>B. Bottiger et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 2001; 357: 1583–5.
<li>E. Ohman et al. Intravenous Thrombolysis in Acute Myocardial Infarction. In: Sixth ACCP Consensus Conference. Chest 2001; 119 (suppl): 253S-277S.
<li>I. Squire et al. Humoral and cellular responses up to 7,5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J 1999; 20: 1245–1252.
<li>The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71–75.
<li>ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–770.
<li>The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682.
<li>T. Wall et al. Accelerated plasminogen activator dose regimens for coronary thrombolysis: the TAMI-7 Study Group. JACC 1992;19:482–489.
<li>R. Califf et al. One-Year Results From the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial. Circulation 1999; 94: 1233-1238.
<li>R. Califf et al. the GUSTO-I Investigators. Selection of thrombolytic therapy for individual patients: development of a clinical model. Am Heart J 1997; 133: 630–639.
<li>The GUSTO Angiographic Investigators. The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction. N Engl J Med 1993; 329: 1615-1622.
<li>J. Purvis et al. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. JACC 1994; 23: 6-10.
<li>The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction. N Engl J Med 1997; 337: 1124–1130.
<li>S. Bleich et al. An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. Am Heart J 1998;
<li>International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346: 329-336. 
<li>The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparsion of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118–1123.
<li>Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet
1999; 354: 716–722.
<li>The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 383–389. 
<li>L. Morrison et al. Mortality and Prehospital Thrombolysis for Acute Myocardial Infarction.  Meta-analysis. JAMA 2000; 283: 2686-2692. 
<li>Task force on the management of chest pain. Eur Heart J 2002; 23: 1153-1176.
<li>E. Bonnefoy et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825-829.
136:741–748.
<li>R. Collins. Drug Therapy: Aspirin, heparin and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction. N Engl J Med 1997; 336: 847-860.
<li>H. White. Further evidence that antithrombotic therapy is beneficial with streptokinase: improved ST resolution and late patency with enoxaparin. Eur Heart J 2002; 23: 1233-1237. 
<li>E. Topol et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281–286.
<li>J. Hsia et al. A comparison between heparin and low-dose aspirin as adjunctive with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial Investigators. N Engl J Med 1990; 323:1433–1437.
<li> D. de Bono et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122–128.
<li>P. Thompson et al. A randomized comparison of intravenous heparin with oral aspirin dipyridamole 24 h after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. Circulation 1991; 83:1534–1542.
<li>C. Granger et al for the GUSTO - I Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Circulation 1996; 93: 870–878.
<li>J. Cairns et al. Antitrombotic Agents in Coronary Heart Disease. In: Sixth ACCP Consensus Conference. Chest 2001; 119 (suppl): 228S-252S.
<li>Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte. Circulation 1994; 90: 1638–1642.
<li>E. Antman. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90: 1624–1630.
<li>Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation 1994;90:1631–1637.
<li>F. Van de Werf. InTIME II: more than a study on lanoteplase. Eur Heart J 2000; 21: 1996-1997.
<li>И.С. Явелов. Применение низкомолекулярных гепаринов в кардиологии. Фарматека 2002; № 7/8: 60-70.
<li>K. Wong et al. Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention. JAMA 2003; 289: 331-342. 
<li>M. Simoons et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction; the AMI-CK study. Eur Heart J 2002; 23: 1282-1290.
<li>The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605–613.
<li>F. Van de Werf. Выступление на XXIV Конгрессе Европейского кардиологического общества. Берлин, сентябрь 2002 г.
<li>L. Wallentin et al. Influence of enoxaparin and early revascularisation on death or myocardial infarction after thrombolysis in myocardial infarction. Eur Heart J 2002; 4 (Abstr. Suppl.): 639.
<li>Prehospital treatment with enoxaparin/tenecteplase reduces reinfarction but increases ICH. www.theHeart.org, ноябрь 2002 г. 
<li>E. Antman. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94: 911–921.
<li>B. Metz et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. JACC 1998; 31: 1493–1498.
<li>J. Weitz. Direct Thrombin Inhibitors in Acute Coronary Syndromes. Present and Future. Circulation 2002; 105: 1004-1011.
<li>The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855–1863.
<li>P. Coussement et al. A synthetic factor-Xa inhibitor ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. European Heart Journal 2001; 22: 1716–1724.
<li>The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905–1914.
<li>A. Lincoff et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002; 288: 2130-2135.
<li>M. Hudson et al. Early Reinfarction After Fibrinolysis Experience From the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Trials. Circulation 2001;104: 1229-1235.
<li>F. Van de Werf, D. Baim.  Reperfusion for ST-Segment Elevation Myocardial Infarction. An Overview of Current Treatment Options. Circulation 2002;105: 2813-2816.
Доложено на XXIV Конгрессе Европейского кардиологического общества. Берлин, сентябрь 2002 г.
</ol>

<p><a href=tlt_txt.htm>Вернуться к статье</a>
</td></tr>
</table>
</HTML>�